Generic Name and Formulations:
Ceftaroline fosamil 400mg, 600mg; per vial; pwd for IV infusion after reconstitution and dilution.
Indications for TEFLARO:
Susceptible bacterial community-acquired pneumonia and acute skin and skin structure infections.
≥18yrs: Give by IV infusion over 5–60mins. Treat skin and skin structure for 5–14 days; treat pneumonia for 5–7days. CrCl >50mL/min: 600mg every 12hrs. Renal impairment (CrCl >30–≤50mL/min): 400mg every 12hrs; (CrCl ≥15–≤30mL/min): 300mg every 12hrs; ESRD (including hemodialysis): 200mg every 12hrs (dose after dialysis on dialysis days).
<2mos: not established. Give by IV infusion over 5–60mins. 2mos–<2yrs: 8mg/kg every 8hrs. ≥2yrs–<18yrs (≤33kg): 12mg/kg every 8hrs; (>33kg): 400mg every 8hrs or 600mg every 12hrs. All: treat for 5–14 days.
Penicillin or other beta-lactam allergy. GI disease (esp. colitis). Monitor for hemolytic anemia. Pregnancy. Nursing mothers.
May cause false (+) direct Coomb's test.
Diarrhea, nausea, vomiting, pyrexia, rash; pseudomembranous colitis, superinfection.
Endocrinology Advisor Articles
- Clinicians May Be Overtreating Older Patients With Diabetes
- Obesity Risk in Infants Born to Women With Diabetes
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Prediabetes a Useful Indicator for Cardiovascular and Renal Risks